Yes, it is appropriate to call this cold weather-induced asthma
The combination of cold weather-triggered breathing problems requiring bronchodilator (albuterol) and controller medication (montelukast) strongly supports an asthma diagnosis, as these symptoms and treatment response align with established diagnostic criteria for asthma.
Diagnostic Reasoning
The clinical presentation meets standard asthma diagnostic criteria 1:
- Recurrent episodes of breathing problems triggered by a typical precipitant (cold air)
- Response to appropriate asthma medications: Both short-acting beta-agonist (albuterol) and controller therapy (montelukast) were prescribed, indicating the clinician recognized this as asthma requiring treatment
- Environmental trigger pattern: Cold weather is a well-recognized asthma trigger that causes bronchoconstriction
According to NAEPP guidelines, a diagnosis should be based on recurrent episodes of symptoms related to typical precipitants (including cold air) that are relieved by beta-adrenergic agents 1. The fact that montelukast was prescribed alongside albuterol suggests the provider identified this as persistent asthma requiring controller therapy, not just isolated symptoms.
Cold Air as an Asthma Trigger
Cold air-induced symptoms represent a specific asthma phenotype. Research demonstrates that cold-sensitive asthmatic patients have distinct characteristics 2:
- More frequent acute exacerbations
- More significant lung function impairment (FEV1/FVC% and FEV1%pred)
- Different inflammatory patterns (often neutrophilic rather than purely eosinophilic)
- Poorer symptom control compared to patients without cold sensitivity
This is not a separate disease entity—it is asthma with cold air as the predominant trigger.
Treatment Appropriateness
The prescribed regimen aligns with guideline-based care 3:
- Albuterol (SABA): Appropriate for quick relief of acute symptoms and as rescue medication
- Montelukast: Appropriate as an alternative controller for mild persistent asthma, particularly in patients who may have difficulty with or be unwilling to use inhaled corticosteroids 3
For cold-sensitive asthma specifically, evidence supports that montelukast combined with other controllers provides better symptom control during cold seasons 4. When montelukast was withdrawn in cold-sensitive patients, control deteriorated significantly (from 83% to 52% achieving control).
Important Caveats
Preferred vs. Alternative Therapy
While the treatment was appropriate, inhaled corticosteroids (ICS) are the preferred first-line controller medication for persistent asthma 3. Montelukast is positioned as an alternative therapy when patients are unable or unwilling to use ICS 3. The choice of montelukast may have been driven by:
- Age-related difficulty with inhaler technique
- Patient/parent preference for oral medication
- Concerns about ICS adherence
Safety Considerations
The FDA issued a Boxed Warning for montelukast regarding neuropsychiatric adverse events 5, 6. Patients and families should be counseled about potential behavioral changes, mood disturbances, or suicidal thinking, though these events are rare 6.
Monitoring Response
If clear benefit is not observed within 4-6 weeks and medication technique/adherence are satisfactory, therapy should be adjusted 5. For cold-triggered symptoms specifically, wearing a mask or scarf in cold weather is recommended as an adjunctive non-pharmacologic intervention 7.
Terminology Precision
The term "cold weather-induced asthma" is clinically appropriate and descriptive. Alternative acceptable terms include:
- Asthma with cold air trigger
- Cold-sensitive asthma
- Asthma with environmental trigger (cold air)
This distinguishes it from exercise-induced bronchoconstriction (EIB), though cold air can also trigger EIB in susceptible individuals 8, 7.